43 results on '"Diessen, Judi"'
Search Results
2. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study
3. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
4. The optimal treatment for patients with stage I non-small cell lung cancer: Minimally invasive lobectomy versus stereotactic ablative radiotherapy – A nationwide cohort study
5. Bronchial Stenosis in Central Pulmonary Tumors Treated With Stereotactic Body Radiation Therapy
6. Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives
7. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients:Results from the randomised ARTFORCE PET-Boost trial
8. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)
9. 1594: Oesophageal toxicity in the phase 2 PET-Boost dose-escalation trial (NCT01024829) in LA-NSCLC
10. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II–III NSCLC
11. Supplementary File 6: Pulmonary Function Tests and Pulmonary Adverse Events by Treatment Arm. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
12. Supplementary File 2: Treatment details. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
13. Supplementary File 5: Esophageal Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
14. Supplementary File 3: Dose Limiting Toxicity. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
15. Supplementary File 1: Supplementary Methods. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
16. Supplementary File 4: Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
17. Supplementary File 8: Olaparib Pharmacokinetics. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
18. Supplementary File 7: Loco-regional control and survival. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
19. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost):Results from a randomised clinical trial
20. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy
21. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab
22. Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols
23. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations
24. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis
25. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
26. Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer
27. Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
28. Local and regional treatment response by (18)FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC
29. Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
30. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis.
31. In response to Park, et al.
32. The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands
33. Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands
34. Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients
35. Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC
36. Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy
37. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations
38. Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols
39. Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
40. Radiotherapy dose and fractionation for stage III NSCLC
41. A Prospective Study: Current Problems in Radiotherapy for Nasopharyngeal Carcinoma in Yogyakarta, Indonesia
42. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
43. Local and regional treatment response by 18 FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.